US EditionSkinCure Oncology Submits GentleBeam™ Image-Guided SRT for FDA Clearance
- SkinCure Oncology submitted its GentleBeam technology to the U.S. Food and Drug Administration for 510 clearance, marking a step in advancing patient-centered care.
- GentleBeam is designed to deliver Image-Guided Superficial Radiation Therapy, a noninvasive treatment option for nonmelanoma skin cancer.
- If cleared, GentleBeam would join SkinCure Oncology's solutions for treating nonmelanoma skin cancers, expanding nonsurgical options.
- Currently, GentleBeam is not available for commercial distribution in the United States until it is FDA cleared.
Insights by Ground AI
Does this summary seem wrong?
19 Articles
19 Articles
All
Left
1
Center
10
Right
1
Coverage Details
Total News Sources19
Leaning Left1Leaning Right1Center10Last UpdatedBias Distribution83% Center
Bias Distribution
- 83% of the sources are Center
83% Center
C 83%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
